Trials / Conditions / Relapsed/Refractory Chronic Lymphocytic Leukemia
Relapsed/Refractory Chronic Lymphocytic Leukemia
5 registered clinical trials studyying Relapsed/Refractory Chronic Lymphocytic Leukemia.
| Status | Trial | Sponsor | Phase |
|---|---|---|---|
| Active Not Recruiting | A Study of GNC-035 in Relapsed or Refractory Chronic Lymphocytic Leukemia and Other Hematological Malignancies NCT05944978 | Sichuan Baili Pharmaceutical Co., Ltd. | Phase 1 / Phase 2 |
| Active Not Recruiting | Safety and Efficacy Study of Epcoritamab in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia and NCT04623541 | Genmab | Phase 1 / Phase 2 |
| Terminated | Ibrutinib lead-in Followed by Venetoclax Plus Ibrutinib in Patients With RR CLL NCT03708003 | Swiss Cancer Institute | Phase 2 |
| Completed | Reduced Intensity Conditioning With Clofarabine, Antithymocyte Globulin (ATG), Total Lymphoid Irradiation (TLI NCT00697684 | Beth Israel Deaconess Medical Center | Phase 1 |
| No Longer Available | Expanded Access Program for Participants Who Completed Study 13-601 and Continue to Clinically Benefit From Ce NCT04757259 | Alexion Pharmaceuticals, Inc. | — |